Table 2. Relationships between baseline CSVD markers and progression of CSVD markers.
| Change of WMH (%) | Incident lacunes | Incident CMBs | ePVS Progression | |
| β (95%CI) | OR (95%CI) | OR (95%CI) | OR (95%CI) | |
| Model 1 | ||||
| WMH volume, per 1% increase | 0.25(0.12,0.38) | 3.78(1.35,10.62) | 4.45(1.41,14.03) | 2.98(1.22,7.28) |
| Lacunes, per No. increase | 0.13(0.03,0.23) | 3.13(1.42,6.88) | 1.33(0.67,2.65) | 2.11(0.94,4.70) |
| CMBs, per No. increase | -0.00(-0.04,0.04) | 0.64(0.28,1.45) | 0.96(0.64,1.44) | 0.83(0.59,1.18) |
| ePVS, per score increase | 0.03(-0.05,0.10) | 0.69(0.26,1.80) | 0.95(0.56,1.63) | 0.23(0.12,0.44) |
| Model 2 | ||||
| WMH volume, per 1% increase | 0.25(0.13,0.38) | 3.96(1.29,12.19) | 4.10(1.29,13.09) | 2.89(1.14,7.32) |
| Lacunes, per No. increase | 0.11(0.01,0.21) | 3.33(1.42,7.82) | 1.35(0.66,2.76) | 2.30(1.00,5.29) |
| CMBs, per No. increase | 0.01(-0.03,0.05) | 0.60(0.21,1.70) | 0.96(0.65,1.43) | 0.81(0.57,1.15) |
| ePVS, per score increase | 0.02(-0.05,0.09) | 0.71(0.26,1.93) | 0.95(0.55,1.64) | 0.23(0.12,0.44) |
| Model 3 | ||||
| WMH volume, per 1% increase | 0.24(0.11,0.37) | 5.50(1.35,22.44) | 4.60(1.39,15.23) | 3.52(1.30,9.53) |
| Lacunes, per No. increase | 0.13(0.03,0.24) | 2.97(1.08,8.13) | 1.34(0.62,2.89) | 2.18(0.90,5.31) |
| CMBs, per No. increase | 0.00(-0.04,0.05) | 0.66(0.24,1.82) | 0.91(0.63,1.33) | 0.81(0.56,1.19) |
| ePVS, per score increase | 0.03(-0.04,0.10) | 0.78(0.24,2.54) | 0.78(0.43,1.42) | 0.20(0.10,0.41) |
| Model 4 | ||||
| WMH volume, per 1% increase | 0.23(0.10,0.36) | 5.86(1.38,24.82) | 4.76(1.38,16.44) | 3.81(1.38,10.49) |
| Lacunes, per No. increase | 0.13(0.03,0.23) | 3.05(1.10,8.47) | 1.35(0.62,2.93) | 2.28(0.93,5.60) |
| CMBs, per No. increase | 0.01(-0.03,0.05) | 0.65(0.25,1.71) | 0.90(0.61,1.32) | 0.84(0.57,1.23) |
| ePVS, per score increase | 0.03 (-0.05,0.10) | 0.77(0.24,2.54) | 0.78(0.42,1.43) | 0.17(0.08,0.37) |
Model 1: unadjusted. Model 2: adjusted for baseline age, sex and interval. Model 3: adjusted for baseline age, sex, interval, BMI, ApoE ε4 carrier, current smoking, hypertension, diabetes, hyperlipidemia, cardiogenic disease. Model 4: additionally adjusted for antihypertensive, antidiabetic, lipid lowering, and antiplatelet / anticoagulation medications.
Abbreviations: CSVD = cerebral small vessel disease; WMH = white matter hyperintensities; CMBs = cerebral microbleeds; ePVS = enlarged perivascular spaces.